AstraZeneca PLC ADR (AZN)

Currency in USD
92.14
+0.59(+0.64%)
Closed·
93.33+1.19(+1.29%)
·
AZN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
91.9493.10
52 wk Range
61.2494.02
Key Statistics
Prev. Close
91.55
Open
92.52
Day's Range
91.94-93.1
52 wk Range
61.24-94.02
Volume
3.54M
Average Volume (3m)
5.54M
1-Year Change
38.29%
Book Value / Share
29.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AZN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
98.96
Upside
+7.40%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

AstraZeneca PLC ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

AstraZeneca ADR Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
94300

AstraZeneca PLC ADR SWOT Analysis


Oncology Powerhouse
AstraZeneca's strong oncology portfolio drives growth, with flagship drugs like Imfinzi showing impressive revenue increases despite market challenges
Pipeline Potential
Explore AstraZeneca's diverse pipeline, including promising treatments in hematologic malignancies and the highly anticipated AVANZAR trial results
Strategic Growth
Delve into AstraZeneca's strategic acquisitions and partnerships, enhancing its portfolio and pipeline across multiple therapeutic areas
Market Outlook
Analysts project positive growth, with price targets ranging from $85 to $89, reflecting confidence in AstraZeneca's financial health and market position
Read full SWOT analysis

AstraZeneca PLC ADR Earnings Call Summary for Q2/2025

  • AstraZeneca's Q2 2025 EPS of $2.17 surpassed forecasts by 99.08%, with revenue reaching $14.46 billion, up 11% year-over-year
  • Stock price rose 6.63% in pre-market trading following strong results, with the company on track for its $80 billion revenue target by 2030
  • Double-digit growth across key markets, driven by oncology and biopharmaceuticals; R&D costs increased 17%, representing 23% of total revenue
  • CEO Pascal Soriot emphasized long-term growth vision to 2030 and beyond, highlighting significant progress towards strategic ambitions
  • Company forecasts high single-digit revenue growth and low double-digit EPS growth, with focus on oncology, obesity, and rare disease markets
Last Updated: 21/08/2025, 10:58
Read Full Transcript

Compare AZN to Peers and Sector

Metrics to compare
AZN
Peers
Sector
Relationship
P/E Ratio
30.6x25.3x−0.6x
PEG Ratio
0.670.730.00
Price/Book
6.3x4.7x2.6x
Price / LTM Sales
4.9x3.8x3.2x
Upside (Analyst Target)
12.5%25.1%41.8%
Fair Value Upside
Unlock20.8%5.1%Unlock

Analyst Ratings

10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 98.96
(+7.40% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy105.00+13.96%95.00Maintain09/12/2025
BofA Securities
Buy108.50+17.76%91.70Maintain25/11/2025
Leerink Partners
Buy87.00-5.58%85.00Maintain10/11/2025
UBS
Buy4,925.00+5,245.13%4,260.00Maintain11/09/2025
BNP Paribas Exane
Buy75.00-18.60%-New Coverage15/04/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.02%
Dividend Yield
1.67%
Industry Median 2.50%
Annualised payout
1.54
Paid semi-annually
5-Years Growth
+2.25%
Growth Streak

Earnings

Latest Release
Nov 06, 2025
EPS / Forecast
2.38 / 1.16
Revenue / Forecast
15.19B / 14.76B
EPS Revisions
Last 90 days

People Also Watch

459.21
VRTX
-0.24%
297.58
ADSK
-0.96%
674.14
INTU
-0.16%
331.49
AMGN
+0.03%
1,071.64
LLY
-0.45%

FAQ

What Is the AstraZeneca ADR (AZN) Share Price Today?

The live AstraZeneca ADR share price today is 92.14

What Stock Exchange Does AstraZeneca ADR (AZN) Trade On?

AstraZeneca ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for AstraZeneca ADR?

The stock symbol (also called a 'ticker') for AstraZeneca ADR is "AZN."

Does AstraZeneca ADR Pay Dividends? What’s The Current AZN Dividend Yield?

Yes, AZN Pays Dividends to its Shareholders. The current AstraZeneca ADR dividend yield is 1.67%.

What Is the Current AstraZeneca ADR Market Cap?

As of today, AstraZeneca ADR market capitalisation is 288.09B.

What Is AstraZeneca ADR's (AZN) Earnings Per Share (TTM)?

The AstraZeneca ADR EPS is currently 6.02 (Trailing Twelve Months).

When Is the Next AstraZeneca ADR Earnings Date?

AstraZeneca ADR's next earnings report will be released on 10 Feb 2026.

Is AZN a Buy or Sell From a Technical Analyst Perspective?

Based on today's AstraZeneca ADR moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has AstraZeneca ADR Stock Split?

AstraZeneca ADR has split 2 times. (See the AZN stock split history page for full effective split date and price information.)

How Many Employees Does AstraZeneca ADR Have?

AstraZeneca ADR has 94300 employees.

What is the current trading status of AstraZeneca ADR (AZN)?

As of 24 Dec 2025, AstraZeneca ADR (AZN) is trading at a price of 92.14, with a previous close of 91.55. The stock has fluctuated within a day range of 91.94 to 93.10, while its 52-week range spans from 61.24 to 94.02.

What Is AstraZeneca ADR (AZN) Price Target According to Analysts?

The average 12-month price target for AstraZeneca ADR is USD98.95545, with a high estimate of USD108.53 and a low estimate of USD81. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +7.40% Upside potential.

What Is the AZN Premarket Price?

AZN's last pre-market stock price is 92.54. The pre-market share volume is 21,810.00, and the stock has decreased by 0.99, or 1.08%.

What Is the AZN After Hours Price?

AZN's last after hours stock price is 93.33, the stock has decreased by 1.19, or 1.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.